Hypercalcaemia is commonly seen in the context of parathyroid dysfunction and malignancy and, when severe, can precipitate life-threatening sequelae. The differential of hypercalcaemia is broad and can be categorized based on parathyroid hormone (PTH) levels. The acute management of severe hypercalcaemia is discussed along with a brief review of therapeutic advances in the field.
Atula, S.T., Tahtela, R.K., Nevalainen, J.I. and Pylkkanen, L.H. ( 2006) Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. Acta Oncologica42: 735-740.
2.
Ayuk, J., Cooper, M.S. and Gittoes, N.J.L. ( 2010) New perspectives in the management of primary hyperparathyroidism . Ther Adv Endocrin Metab, doi:10.1177/2042018810382326.
3.
Bilezikian, J.P. ( 2006) Osteonecrosis of the jaw - do bisphosphonates pose a risk ? N Eng J Med355: 2278-2281.
4.
Body, J.J., Lipton, A., Gralow, J., Steger, G., Gao, G., Yeh, H. et al. (2010) Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res25: 440-446.
5.
British National Formulary (2010) British National Formulary 60, Online edition. http://www.bnf.org.
6.
Broadus, A.E., Mangin, M., Ikeda, K., Insogna, K.L., Weir, E.C., Burtis, W.J. et al. (1988) N Engl J Med319: 556-563.
7.
Cannon, J., Lew, J. and Solorzano, J.(2010) Parathyroidectomy for hypercalcemic crisis: 40 years’ experience and long-term outcomes. Surgery148: 807-813.
8.
Carroll, R. and Matfin, G.(2010) Endocrine and metabolic emergencies: hypocalcaemia. Ther Adv Endocrinol Metab1: 29-33.
9.
Chesnut, C.H., Azria, M., Silverman, S., Engelhardt, M., Olson, M. and Mindeholm, M. ( 2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int19: 479-491.
10.
Chitambar, C.R. ( 2010) Medical applications and toxicities of gallium compounds . Int J Environ Res Public Health7: 2337-2361.
11.
Cvitkovic, F., Armand, J.-P., Tubiana-Hulin, M., Rossi, J.-F. and Warrell, R. ( 2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia . Cancer J12: 47-53.
12.
Fili, S., Karalaki, M. and Schaller, B.(2009) Therapeutic implications of osteoprotegrin. Cancer Cell Int9: 26.
13.
Hewison, M., Burke, F., Evans, K.N., Lammas, D.A., Sansom, D.M., Liu, P. et al. (2007) Extra-renal 25-hydroxyvitamin D3-1-hydroxylase in human health and disease. J Steroid Biochem103: 316-321.
14.
Holick, M.F. ( 2007) Vitamin D deficiency. N Engl J Med357: 266-281.
15.
Igbal, A.A., Burgess, E.H., Gallina, D.L., Nanes, M.S. and Cook, C.B. ( 2003) Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis. Endocr Pract9: 517-521.
16.
Joshie, D., Center, J.R. and Eisman, J.A. ( 2009) Investigation of incidental hypercalcaemia. BMJ339: b4613.
17.
LeGrand, S.B., Leskuski, D. and Zama, I. ( 2008) Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med149: 259-263.
18.
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H.D. et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol19: 558-567.
19.
Marcocci, C., Chanson, P., Shoback, D., Bilezikian, J., Fernandez-Cruz, L., Orgiazzi, J. et al. (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocr Metab94: 2766-2772.
20.
Matfin, G. ( 2009) Disorders of fluid balance and electrolytes, In: Porth, C.M. and Matfin, G. (eds). Pathophysiology: Concepts of Altered Health States , 8th edn, Wolters Kluwer Health : Philadelphia, PA.
21.
Purohit, O.P., Radstone, C.R., Anthony, C., Kanis, J.A. and Coleman, R.E. ( 1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Brit J Cancer72: 1289-1293.
22.
Ralston, S.H., Thiebaud, D., Herrmann, Z., Steinhauer, E.U., Thurlimann, B., Walls, J. et al. (1997) Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Brit J Cancer75: 295-300.
23.
Reszka, A.A. ( 2010) Bisphosphonate mechanisms of action. Contemporary Endocrinology: Osteoporosis2nd edn. Humana Press: New York, NY.
24.
Selby, P. ( 2002) Normal calcium homeostasis. Clin Rev Bone Miner Metab1: 3-9.
25.
Shoback, D., Sellmeyer, D. and Bikle, D.D. ( 2007) Metabolic bone disease, In: Shoback, D. and Gardner, D.G. (eds). Greenspan’s Basic and Clinical Endocrinology, 8th edn. McGraw Hill: New York.
26.
Silverberg, S.J., Rubin, M.R., Faiman, C., Peacock, M., Shoback, D.M., Smallridge, R.C. et al. (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocr Metab92: 3803-3808.
27.
Stewart, A. ( 2005) Hypercalcaemia associated with cancer. N Engl J Med352: 373-379.
28.
Tanaka, S., Nakamura, K., Takahasi, N. and Suda, T. ( 2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev208: 30-49.
29.
von Moos, R., Caspar, C.B., Thurlimann, B., Angst, R., Inauen, R., Greil, R. et al. (2008) Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann Oncol19: 1266-1270.
30.
Yamada, T., Muguruma, H., Yano, S., Ikuta, K., Ogino, H., Kakiuchi, S. et al. (2009) Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. Mol Cancer Ther8: 119-126.
